Who is sponsoring NCT04228094?

NCT04228094 is sponsored by Universitat de Girona.

What drugs are being tested in NCT04228094?

Interventions in NCT04228094: TDApp1: an eHealth intervention.

What condition does NCT04228094 study?

NCT04228094 studies Attention Deficit-hyperactivity Disorder.

Is NCT04228094 still recruiting?

NCT04228094 is currently completed. Last updated 22 September 2022.

Last reviewed 2022-09-22 · How we verify

NCT04228094

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assesment of TDApp1 an eHelath Tool to Make Therapeutic Recommendations for Patients With ADHD

Completed Last updated 22 September 2022

What this trial tests

trial testing TDApp1: an eHealth intervention in Attention Deficit-hyperactivity Disorder in 33 participants. Completed in 9 May 2022.

Timeline

10 August 2020

Primary endpoint
9 May 2022

9 May 2022

Quick facts

Lead sponsor	Universitat de Girona
Status	Completed
Study type	OBSERVATIONAL
Enrollment	33
Start date	10 August 2020
Primary completion	9 May 2022
Estimated completion	9 May 2022
Sites	1 location across Spain

Drugs / interventions tested

TDApp1: an eHealth intervention

Conditions studied

Attention Deficit-hyperactivity Disorder — all drugs for Attention Deficit-hyperactivity Disorder →

Sponsor

Universitat de Girona

Who can join

Adults 6 to 65, any sex, with Attention Deficit-hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 3-week open label, one group study to determine the agreement between the pharmacological treatment recommended by TDApp1 and the interventions recommended by relevant clinical practice guidelines.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Assessing TDApp: An AI-based clinical decision support system for ADHD treatment recommendations.
Baykova E, Raya Ò, Lombardía C, Gonzalvo B, et al · · 2025 · cited 1× · PMID 40917247 · DOI 10.3389/fpsyt.2025.1582746
APPRAISE-RS: Automated, updated, participatory, and personalized treatment recommender systems based on GRADE methodology.
López B, Raya O, Baykova E, Saez M, et al · · 2023 · cited 1× · PMID 36798764 · DOI 10.1016/j.heliyon.2023.e13074

Verify or expand the search:

Other Universitat de Girona trials

Trials by the same sponsor.

NCT05651685 — Treatment Recommendations for Patients With ADHD TDApp2 · completed
NCT05387291 — Nursing Intervention Program in the Management of Parental Anxiety and Infant Pain in the Surgical Process of Children t · NA · completed
NCT05096806 — Effects of Semi-standarized Acupuncture in Chronical Symptomatic Osteoarthritis of the Knee Through: A Randomized Contro · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04228094 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitat de Girona
Last refreshed: 22 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04228094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing